Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines

Role of alum as adjuvant in Clostridial vaccines

Liposomes as adjuvant for combination vaccines.

In the present study tetanus toxoid (TT) loaded liposomes and diphtheria toxoid (DT) loaded liposomes were prepared by reverse phase evaporation method and after combining these two vaccines the potential advantages were investigated. Prepared systems were characterized for the size, shape and entrapment efficiency. SDS-PAGE analysis of TT and DT was also performed. The selected liposomal formu...

Corrigendum: Recent Advances in Lentiviral Vaccines for HIV-1 Infection

[This corrects the article on p. 243 in vol. 7, PMID: 27446074.].

Recent Advances in Lentiviral Vaccines for HIV-1 Infection

The development of an effective HIV vaccine to prevent and/or cure HIV remains a global health priority. Given their central role in the initiation of adaptive immune responses, dendritic cell (DC)-based vaccines are being increasingly explored as immunotherapeutic strategies to enhance HIV-specific T cells in infected individuals and, thus, promote immune responses that may help facilitate a f...

Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.

Epstein-Barr virus (EBV) is a potent growth-transforming agent of human B cells. It has previously been shown that viral latent membrane protein 1 (LMP1) is essential for EBV-induced transformation of normal B cells and contributes to maintenance of latency in vitro. Using the EBV-positive Burkitt's lymphoma line P3HR1-c16, which lacks LMP1 during latency and which can readily be activated into...